arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

AbbVie Inc.

ABBV
$245.14 ▲ +1.25 (+0.51%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Neutral
auto_awesome

Analytical Summary

AbbVie Inc. demonstrates solid fundamentals with strength in Debt to Equity. However, watch Return on Common Equity (%) which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $433.9B
Dividend Yield 0.71%
Revenue Growth 12.4%
Op. Margin 26.6%
ROIC -40.2%
FCF / Share $2.01
Trailing P/E 628.6x
Price / Book
FCF Yield 0.8%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Aug 7, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$15.00B
↑ +12.4%
Net Income Profit after all expenses
$695.00M
↓ -46.0%
Operating Margin Operating profit as % of sales
26.6%
↓ -2.7% 81th
FCF / Share Free cash flow per share
$2.01
↑ +154.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
76
Returns
6
Financial Health
87
Cash Quality
94

Dividend History

Dividend / share · sourced from SEC filings
$6.65 Latest / share
+5.7% YoY
+12.9% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 59 quarters